Summary:
NeuroStudies.net is conducting a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy And Safety Study of Crenezumab in Patients With Prodromal to Mild Alzheimer's Disease
Qualified Participants Must:
• Be between 50 and 85 years of age
• Have a study partner
• Have memory loss
Qualified Participants May Receive:
Compensation for their time and travel.